FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Stock analysts at Leerink Partnrs lowered their FY2024 EPS estimates for shares of Trevi Therapeutics in a report issued on Tuesday, January 21st. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings per share of ($0.49) for the year, down from their previous estimate of ($0.48). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.49) EPS and FY2026 earnings at ($0.48) EPS.

Several other brokerages also recently weighed in on TRVI. B. Riley reiterated a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. HC Wainwright raised their price target on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, January 8th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $9.31.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $3.78 on Thursday. The firm has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $3.20. Trevi Therapeutics has a 1-year low of $1.30 and a 1-year high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter in the previous year, the business earned ($0.08) EPS.

Institutional Trading of Trevi Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TRVI. SG Americas Securities LLC raised its position in Trevi Therapeutics by 14.5% in the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock valued at $110,000 after purchasing an additional 3,387 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares during the period. American Century Companies Inc. lifted its position in Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares in the last quarter. MAI Capital Management boosted its holdings in Trevi Therapeutics by 0.7% in the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after acquiring an additional 8,789 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock valued at $73,000 after acquiring an additional 11,450 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.